7. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is another large-cap biotech name that deserves serious attention because it combines commercial strength, deep R&D, immunology exposure, ophthalmology assets, and shareholder returns. Based on latest market data, Regeneron traded at $698.25, with a market capitalization of about $75.20 billion and a P/E ratio near 17.05. That valuation is interesting because Regeneron is not a speculative biotech; it is a profitable innovation machine with major marketed products and a large clinical pipeline.
In Q1 2026, Regeneron reported revenue of $3.6 billion, up 19% from the prior year. Dupixent global net sales, recorded by Sanofi, increased 33% to $4.9 billion, while EYLEA HD U.S. net sales increased 52% to $468 million. Total EYLEA HD and EYLEA U.S. net sales declined 10% to $941 million, showing that there are still pressures in the eye-disease franchise, but the broader company remains strong. Regeneron also reported GAAP EPS of $6.75 and non-GAAP EPS of $9.47, while announcing a new $3.0 billion share repurchase program.
CEO Leonard Schleifer said Regeneron achieved “strong double-digit growth on both the top and bottom line” while continuing to invest in nearly 50 clinical-stage product candidates. That pipeline depth is one of the reasons REGN remains a top biotech stock despite investor concerns about EYLEA competition. The company also continues to expand Dupixent indications, and its business model benefits from both internal discovery and disciplined capital allocation. The risk is that ophthalmology sales pressure, payer dynamics, and drug-pricing politics can weigh on sentiment. But with strong revenue growth, a deep pipeline, profitable operations, and active buybacks, Regeneron remains one of the best biotech stocks for investors who want scale, innovation, and financial strength in one package.
Click next to see the following stock...
